These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8136753)

  • 1. Allogeneic bone marrow transplantation combined with multiple anti-HIV-1 treatment in a case of AIDS.
    Contu L; La Nasa G; Arras M; Pizzati A; Vacca A; Carcassi C; Ledda A; Boero R; Orrù S; Pintus A
    Bone Marrow Transplant; 1993 Dec; 12(6):669-71. PubMed ID: 8136753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
    Isola LM; Scigliano E; Skerrett D; Shank B; Ross V; Najfeld V; Fruchtman S
    Bone Marrow Transplant; 1997 Dec; 20(12):1033-7. PubMed ID: 9466275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AIDS-related complex treated by antiviral drugs and allogeneic bone marrow transplantation following conditioning protocol with busulphan, cyclophosphamide and cyclosporin.
    Torlontano G; Di Bartolomeo P; Di Girolamo G; Angrilli F; Verani P; Maggiorella MT; Dragani A; Iacone A; Papalinetti G; Olioso P
    Haematologica; 1992; 77(3):287-90. PubMed ID: 1427437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma.
    Holland HK; Saral R; Rossi JJ; Donnenberg AD; Burns WH; Beschorner WE; Farzadegan H; Jones RJ; Quinnan GV; Vogelsang GB
    Ann Intern Med; 1989 Dec; 111(12):973-81. PubMed ID: 2512828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB; Myers S; Devine S; Larson RA; Williams SF; Park CL; O'Toole K; Chandler C; Topper RL
    Bone Marrow Transplant; 1992 Jan; 9(1):41-7. PubMed ID: 1543948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning.
    Mehta J; Powles RL; Mitchell P; Rege K; De Lord C; Treleaven J
    Bone Marrow Transplant; 1994 May; 13(5):583-7. PubMed ID: 8054911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
    Bertz H; Potthoff K; Mertelsmann R; Finke J
    Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow transplantation for the treatment of immune deficiency states.
    Lenarsky C; Parkman R
    Bone Marrow Transplant; 1990 Dec; 6(6):361-9. PubMed ID: 1965792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
    Avalos BR; Klein JL; Kapoor N; Copelan EA
    Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulphan and cyclophosphamide.
    Wiktor-Jedrzejczak W; Szczylik C; Matej H; Pojda Z; Ratajczak MZ; Myc A; Siekierzyński M; Kansy J; Kłos M; Rybicki Z
    Arch Immunol Ther Exp (Warsz); 1991; 39(4):441-7. PubMed ID: 1821620
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.
    Maschan AA; Kryzanovskii OI; Yourlova MI; Skorobogatova EV; Pashanov ED; Potapova YE; Timonova LA; Bogatcheva NY; Samochatova EV; Roumjantzev AG
    Bone Marrow Transplant; 1997 Feb; 19(4):385-7. PubMed ID: 9051250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
    Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
    Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.